SynthesisFrontiers in endocrinology2026
Influencing factors of type 2 diabetes remission: a systematic review and meta-analysis.
Synthesis in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To identify factors influencing type 2 diabetes mellitus (T2DM) remission and compare differences across intervention types and remission criteria. Methods: T2DM remission was defined as HbA1c < 6.5% (48 mmol/mol), measured at least 3 months after cessation of glucose-lowering pharmacotherapy. Relevant literature on factors influencing T2DM remission was searched in English-language databases, with the search updated through March 2026. Meta-analysis was performed using Review Manager 5.4 and Stata 18.0 software. Results: A total of 36 studies were included. Higher fasting plasma glucose (OR = 0.99, 95% CI = [0.99, 1.00], P < 0.001), higher glycated hemoglobin (OR = 0.91, 95% CI = [0.88, 0.94], P < 0.001), longer disease duration (OR = 0.89, 95% CI = [0.88, 0.90], P < 0.001), and a greater number of oral antidiabetic agents (OR = 0.56, 95% CI = [0.38, 0.81], P = 0.002) were associated with lower odds of remission. A greater percentage of total weight loss was associated with higher odds of remission (OR = 1.05, 95% CI = [1.04, 1.07], P < 0.001). In surgical interventions, a higher body mass index (OR = 1.05, 95% CI = [1.02, 1.08], P = 0.002) was associated with higher odds of remission, whereas older age (OR = 0.96, 95% CI = [0.94, 0.98], P < 0.001) and insulin use (OR = 0.34, 95% CI = [0.23, 0.52], P < 0.001) were associated with lower odds of remission. In non-surgical interventions, alcohol cessation was associated with higher odds of remission (OR = 1.14, 95% CI = [1.05, 1.26], P < 0.001), while factors influencing lower odds of remission included smoking (OR = 0.90, 95% CI = [0.86, 0.94], P < 0.001), continued alcohol consumption (OR = 0.90, 95% CI = [0.84, 0.95], P < 0.001), and a higher body mass index (OR = 0.89, 95% CI = [0.86, 0.92], P < 0.001). Gender, race/ethnicity, physical exercise, intermittent fasting, HOMA-IR and C-peptide level were not associated with T2DM remission. Conclusion: T2DM remission is influenced by multiple factors, with BMI showing opposite associations by intervention type. Future large-scale, prospective studies are needed to validate these findings. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420261295582.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.